From what Susan says, it sounds like it's her insurance company that's not approving the Herceptin. Has anyone else had a problem with insurance companies disallowing payment for Herceptin for node neg (and hormone neg) patients?
Ahh.. maybe I do have something to contribute:
Herceptin® Improves Survival in HER2-positive Early Breast Cancer (1/8/2007)
According to updated results from the Herceptin Adjuvant (HERA) study, one year of Herceptin® (trastuzumab) following chemotherapy results in better overall survival than chemotherapy alone in women with HER2-positive early breast cancer. These results were published in the Lancet.
http://www.ufscc.ufl.edu/Patient/can...cernews&cid=18
__________________
Janet in Rowlett Texas
Dx July 2006 IDC 1.8cm, ER-/PR- HER2+ (FISH 7), KI67 High (60%) grade 3, TOPO II neg
Aug2006: lumpectomy, SNB (4 nodes neg), Stage 1
Jan 2007: Finished 6 cycles of TCH (Taxotere, Carboplatin, Her ceptin). Then Herceptin every 3 weeks.
Feb 2007: Completed Radiation
May 2007: Stopped Herceptin due to low LVEF (49%)
July 2007: LVEF now 44% -- starting Coreg
May 2008: Heart NORMAL! Yippee.
|